Revive Therapeutics CSE: RVV | OTC: RVVTF Revive Therapeutics is focused on the R&D and sale of cannabinoid-based products, recently expanding into the psychedelics industry more broadly. Revive Therapeutics$0.5100-1.92%$0.0100 Latest News Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics November 18, 2020 Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin November 11, 2020 Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 October 26, 2020 Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds October 20, 2020 Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 September 29, 2020 Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs September 21, 2020 Join our Newsletter Get the latest Company updates delivered to straight to your inbox. Leave this field empty if you're human: